Your browser doesn't support javascript.
loading
Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis.
Naeimifar, Atefeh; Samadi, Aniseh; Ahmad Nasrollahi, Saman; Fattahi, Azam; Ghasemi, Zeinab; Azizzadeh-Roodpishi, Shadi; Malakooti, Shiva; Ehsani, Amir Hooshang; Firooz, Alireza; Dowlatiy, Yahya.
Afiliação
  • Naeimifar A; Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Samadi A; Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahmad Nasrollahi S; Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
  • Fattahi A; Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
  • Ghasemi Z; Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Azizzadeh-Roodpishi S; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Malakooti S; Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
  • Ehsani AH; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Firooz A; Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
  • Dowlatiy Y; Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Mycoses ; 63(5): 517-524, 2020 May.
Article em En | MEDLINE | ID: mdl-32048351
ABSTRACT

BACKGROUND:

Efinaconazole is non-lacquer-based with a low surface tension that efficiently targets delivery of active ingredient into the nail and nail bed.

OBJECTIVES:

To develop an optimal, stable formulation of efinaconazole topical solution 10% (ETS10).

METHODS:

We evaluated the safety and efficacy of ETS10 on 10 Iranian participants in a pilot, single-group and before-after clinical study, for up to 8 weeks in onychomycosis.

RESULTS:

The study showed reasonable results concerning the short period of treatment. During the period of storage, the formulation showed no variation in colour, odour and pH. The average pH at initial, 1st, 6th and 12th months was 4.65, 4.64, 4.65 and 4.64, respectively. The assay of an active pharmaceutical ingredient in the formulation was desired over the whole period. This indicates that antimicrobial activity has been adequate and efficient. A significant decrease in Investigator Global Assessment (IGA) of the target toenails was also defined as the efficacy endpoint. The median score for IGA at baseline visit was 3 out of 5 which decreased to 2 out of 5 and the decrease was statistically significant.

CONCLUSION:

The study clarifies the new efficacy of ETS10 in subjects with onychomycosis and passed the safety study successfully. These properties may develop the potentiality of ETS10 as a good treatment option for patients with onychomycosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triazóis / Onicomicose / Antifúngicos / Doenças da Unha / Unhas Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mycoses Assunto da revista: MICROBIOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triazóis / Onicomicose / Antifúngicos / Doenças da Unha / Unhas Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mycoses Assunto da revista: MICROBIOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irã